Kangstem Biotech acquires approval of world’s first stem cell treatment for atopic dermatitis

Published: 2017-12-06 16:27:00
Updated: 2017-12-06 15:12:32

Kangstem Biotech(CEO Tae-Hwa Lee) announced on the 5th that it acquired IND(Investigational New Drug) of a Phase III clinical trial for ‘Furestem-AD,’ the world’s first and only stem cell therapeutic product for atopic dermatitis.

In the Phase III clinical trial, total 194 patients with severe a...


- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.

Original Korean

Most Read News

Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.